Comparative Pharmacology
Head-to-head clinical analysis: ATROPEN versus ROBINUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPEN versus ROBINUL.
ATROPEN vs ROBINUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5). Blocks parasympathetic nerve impulses, leading to increased heart rate, bronchodilation, decreased secretions, and mydriasis.
Antimuscarinic; competitively antagonizes acetylcholine at muscarinic receptors, inhibiting parasympathetic nerve impulses.
0.5 to 1 mg IV/IM/SC every 3 to 5 minutes as needed; maximum 3 mg total. For bradycardia: 0.5 mg IV every 3-5 minutes to a maximum of 3 mg. For organophosphate poisoning: 2 mg IV/IM initially, then 2 mg every 5-10 minutes until atropinization.
1-2 mg orally 3-4 times daily; 0.1-0.2 mg intramuscular or intravenous every 6-8 hours as needed.
None Documented
None Documented
Terminal half-life ~2-3 hours in adults; prolonged in elderly and infants due to reduced clearance.
Terminal elimination half-life is approximately 3–4 hours in healthy adults; in elderly or patients with renal impairment, half-life may be prolonged (up to 10 hours). Clinical context: Steady-state achieved within 24 hours; clinically insignificant accumulation with repeated dosing every 4–6 hours.
Renal: ~50% unchanged; hepatic metabolism (hydrolysis) accounts for ~30-40%; fecal: <5%.
Biliary/fecal elimination is the primary route (approximately 80-85% of a dose is recovered in feces as unchanged drug and metabolites); renal excretion accounts for ~15-20% (mostly unchanged drug and active metabolite).
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent